The aim of this study was to evaluate whether a new low-cost strategy for the introduction of magnesium sulphate (MgSO4) for preeclampsia and eclampsia in low-resource areas will result in improved maternal and perinatal outcomes. Doctors and midwives from ten hospitals in Kano, Nigeria, were trained on the use of MgSO4. The trained health workers later conducted step-down training at their health facilities. MgSO4, treatment protocol, patella hammer, and calcium gluconate were then supplied to the hospitals. Data was collected through structured data forms. The data was analyzed using SPSS software. From February 2008 to January 2009, 1,045 patients with severe preeclampsia and eclampsia were treated. The case fatality rate for severe preeclampsia and eclampsia fell from 20.9 % (95 % CI 18.7-23.2) to 2.3 % (95 % CI 1.5-3.5). The perinatal mortality rate was 12.3 % as compared to 35.3 % in a center using diazepam. Introduction of MgSO4 in low-resource settings led to improved maternal and fetal outcomes in patients presenting with severe pre-eclampsia and eclampsia. Training of health workers on updated evidence-based interventions and providing an enabling environment for their practice are important components to the attainment of the Millennium Development Goals (MDG) in developing countries.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10995-012-1105-9DOI Listing

Publication Analysis

Top Keywords

preeclampsia eclampsia
16
maternal fetal
8
fetal outcomes
8
introduction magnesium
8
magnesium sulphate
8
improved maternal
8
health workers
8
training health
8
severe preeclampsia
8
eclampsia
5

Similar Publications

To investigate the correlation between fetoplacental circulation and maternal left ventricular myocardial work (MW) parameters in patients with preeclampsia (PE) and the prediction of fetal hypoxia. Seventy-eight PE patients (PE group) were assigned to intrauterine-hypoxia (27) and non-intrauterine-hypoxia (51) groups, and 45 healthy pregnant women were controls. The receiver operating characteristic (ROC) curve evaluated the diagnostic efficacy of each parameter for fetal intrauterine hypoxia.

View Article and Find Full Text PDF

[Use of hydroxychloroquine in recurrent immune-mediated obstetric diseases (excluding systemic lupus): Scientific basis and evidence].

Rev Med Interne

December 2024

Service de médecine interne et inflammation, département inflammation-immunopathologie-biothérapie (DMU I3), CEREMAIAA, hôpital Saint-Antoine, AP-HP, Sorbonne université, Paris, France.

Hydroxychloroquine (HCQ), a synthetic antimalarial, is recognized for its immunomodulatory, anti-inflammatory and vascular-protective effects. In 20-30% of cases of primary obstetrical antiphospholipid syndrome (APS), the combination of antiplatelet aggregation and prophylactic anticoagulation fails to prevent obstetrical complications, a situation referred to as refractory obstetrical APS. This is partly due to the pro-inflammatory effects of antiphospholipid antibodies (aPL) binding to decidual and trophoblastic cells, which compromise embryonic implantation and placentation.

View Article and Find Full Text PDF

Approach to investigation and management of proteinuria in pregnancy.

Clin Med (Lond)

December 2024

Women's Centre, John Radcliffe Hospital, Oxford University Hospitals, Headley Way, Headington, OX3 9DU. Electronic address:

Pregnancy leads to significant changes in renal physiology which results in increased in glomerular filtration rate (GFR) and enhanced protein excretion. These changes may continue in the postnatal period and might be observed for five to six months after birth. Once confirmed, proteinuria warrants investigation and close surveillance.

View Article and Find Full Text PDF

Preeclampsia is a pregnancy disorder with substantial perinatal and maternal morbidity and mortality. Pregnant women at risk of preeclampsia would benefit from early detection for follow-up, timely interventions and delivery. Several attempts have been made to identify protein biomarkers of preeclampsia, but findings vary with demographics, clinical characteristics, and time of sampling.

View Article and Find Full Text PDF

Pre-eclampsia (PE) is a serious condition affecting 2-8% of pregnancies worldwide, leading to high maternal and fetal morbidity and mortality. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as potential biomarkers for various pregnancy-related pathologies, including PE. MiRNAs in plasma and serum have been extensively studied, but urinary miRNAs remain underexplored, especially during early pregnancy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!